2024 年半年度非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金 | | 占用方与上市 | 上市公司核算 | 2024 | 年期初占用 | 2024 年半年度占用 | 2024 年半年度占 | 2024年半年度 | 2024 年半年度期 | 占用形成原 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 占用 | 资金占用方名称 | 公司的关联关 | 的会计科目 | 资金余额 | | 累计发生金额（不含 | 用资金的利息(如 | 偿还累计发生 | 末占用资金余额 | 因 | 占用性质 | | | | 系 | | | | 利息） | 有) | 金额 | | | | | 控股股东、实际 | | | | | | | | | | | | | 控制人及其附 | | | | | | | | | | | | | 属企业 | | | | | | | | | | | | | 小计 | | | | | | | | | | | | | 前控股股东、实 | | | | | | | | | | | | | 际控制 ...

Financial Performance - The company reported a significant increase in revenue for the first half of 2024, with total revenue reaching RMB 500 million, representing a 20% year-over-year growth[6]. - The company's operating revenue for the reporting period was ¥394,627,327.90, a decrease of 23.91% compared to the same period last year[11]. - Net profit attributable to shareholders was ¥11,231,946.27, down 86.81% year-on-year[11]. - The net profit after deducting non-recurring gains and losses was ¥5,838,405.63, reflecting a decline of 92.33% compared to the previous year[11]. - The basic earnings per share were ¥0.03, a decrease of 85.71% from ¥0.21 in the same period last year[11]. - The total assets at the end of the reporting period were ¥2,567,017,802.81, down 5.14% from the end of the previous year[11]. - The net assets attributable to shareholders decreased by 2.26% to ¥1,632,278,434.63 compared to the end of the previous year[11]. - The company reported a net cash flow from operating activities of -¥108,387,936.26, an improvement of 4.42% from -¥113,402,819.61 in the previous year[11]. - The company achieved a net increase in cash and cash equivalents of -¥352,182,384.23, a decline of 109.85% compared to the previous year, mainly due to increased cash outflows from investment activities[64]. - The company reported a total operating cash outflow of 364,744,941.28 CNY, which is lower than 420,489,155.30 CNY in the previous period, suggesting improved operational efficiency[148]. Strategic Initiatives - The company has set a revenue guidance for the second half of 2024, projecting a growth rate of 25% compared to the first half[6]. - New product launches are expected to contribute an additional RMB 100 million in revenue by the end of 2024[6]. - The company is investing RMB 50 million in research and development for new technologies aimed at enhancing software capabilities[6]. - Market expansion efforts include entering two new provinces, which are projected to increase market share by 10%[6]. - The company plans to implement a new marketing strategy focusing on digital channels, aiming for a 30% increase in customer engagement[6]. - The company is focused on promoting comprehensive health services, aligning with the national "14th Five-Year Plan" for public health, which aims to provide full-cycle health services and improve healthcare quality[17]. - The company aims to enhance market regulatory efficiency through the integration of information technology and regulatory practices, contributing to a modernized market supervision system[28]. Industry Focus - The healthcare sector is a key focus area for the company, aligning with national goals for health system reform and digital transformation in healthcare services[16]. - The company emphasizes the importance of digital transformation in the healthcare sector, driven by new technologies such as cloud computing, big data, and 5G, to enhance public hospital management and service quality[17]. - The company is committed to supporting the "Healthy China" initiative and the construction of a "Digital China" through its services and solutions[31]. - The company is a core developer of the national medical insurance information platform and a strategic partner of the Ministry of Human Resources and Social Security[29]. - The company has a leading position in the healthcare sector, providing comprehensive solutions for high-quality hospital development, smart hospitals, and healthcare management[30]. Risks and Challenges - The company has identified potential risks related to market competition and regulatory changes, with strategies in place to mitigate these risks[1]. - The company faces market competition risks due to increasing market scale and new entrants, requiring enhanced capabilities to maintain growth in emerging sectors[88]. - There is a risk of technological lag if the company fails to keep pace with policy changes affecting its core business, which is closely tied to government regulations[89]. - Rising operational costs, particularly in labor, pose a significant challenge to the company's profitability as average wage levels continue to increase[90]. - The company anticipates potential declines in service fees for its operational services due to market expansion and increased competition[91]. Investment and Development - The company completed significant equity investments in Shanxi Jiuyuan Aisi Software Co., Ltd. and Guizhou Jiuyuan Yinhai Software Co., Ltd., totaling CNY 18,800,000.00 and CNY 10,000,000.00 respectively[75]. - The company has launched innovative applications for medical insurance electronic credentials and mobile payments, with over 300 hospitals in regions like Sichuan and Guizhou adopting these services[33]. - The company has developed a comprehensive "AI + Smart Medical Insurance" product and service system, including various industry data models for fraud detection, predictive analysis, and monitoring, contributing to innovative healthcare solutions[55]. - The company has launched a new generation hospital operation management system (HRP) at the CHINC conference, enhancing hospital operational capabilities[34]. - The company has expanded its digital human resources solutions, covering 25 provinces and undertaking 12 major social welfare information projects[36]. Corporate Governance - The company held its 2023 annual general meeting on April 23, 2024, with a participation rate of 39.87%[98]. - There were no changes in the company's directors, supervisors, or senior management during the reporting period[100]. - The company has not implemented any equity incentive plans or employee stock ownership plans during the reporting period[100]. - The company continues to strengthen its environmental management and compliance with national laws and regulations[101]. - The company has no major related party transactions during the reporting period[110]. Market Presence - The company serves over 700 million people across 29 provinces and 240+ cities, with partnerships in 160,000 medical institutions[29]. - The company has a strong market presence in various sectors, including healthcare, social security, and housing finance, maintaining a leading market share[29]. - The company has been recognized as a national high-tech enterprise and has been awarded multiple accolades, including being among the top ten innovative software companies in China[29]. - The company has expanded its market coverage by winning contracts for the "One Card" management platform in Xinjiang and Dazhou, Sichuan, enhancing its service capabilities[37]. Financial Management - The company has not engaged in any securities or derivative investments during the reporting period[77]. - The cumulative amount of unused raised funds is CNY 21,857.01 million, with 49.38% of the total raised funds remaining unutilized[77]. - The company reported a decrease in restricted shares due to the release of shares held by former executives, including a reduction of 2,654,110 shares from Mr. Zhan Kaiming[126]. - The company has not reported any further developments regarding the equity reform as of the report date[122]. - The company’s total assets at the end of the reporting period were CNY 562,623,104.36[159].

证券代码：002777 证券简称：久远银海 公告编号：2024-024 四川久远银海软件股份有限公司 第六届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 四川久远银海软件股份有限公司第六届董事会第七次会议通知于 2024 年 8 月 16 日以专人送达、电话、电子邮件等方式送达全体董事、监事及高级管理人员。会议 于 2024 年 8 月 27 日以通讯方式召开，会议应参加表决的董事 9 人，实际参加表决 的董事 9 人。会议的召集、召开符合有关法律、法规和公司章程的规定。 公司严格按照《证券法》、《深圳证券交易所股票上市规则》及《公司章程》等 有关规定和要求，编制完成了《公司2024年半年度报告》和《公司2024年半年度报 告摘要》。 表决结果：9 票同意，0 票反对，0 票弃权。该议案获得通过。 《公司 2024 年 半 年 度 报 告 》 具 体 内 容 详 见 巨 潮 资 讯 网 （http://www.cninfo.com.cn）。 《公司2024年半年度报告摘要》具体内容详见《证券时报》、《中国证 ...

第六届董事会独立董事第六次专门会议决议 独立董事认为：公司编制的《2024年半年度募集资金存放与使用情况的专项 报告》体现了公司募集资金存放和使用的实际情况。公司已及时、真实、准确、 完整地披露了募集资金使用的相关信息，不存在募集资金存放、使用、管理及披 露违规情形。综上，我们同意公司编制的《2024年半年度募集资金存放与使用情 况的专项报告》。 (以下空白） 四川久远银海软件股份有限公司 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》等相 关法律法规、规范性文件以及《四川久远银海软件股份有限公司独立董事专门会 议工作制度》的相关规定，四川久远银海软件股份有限公司（以下简称"公司" 或"本公司"）于2024年8月27日以通讯方式召开第六届董事会独立董事第六次专 门会议。 本次会议由公司过半数独立董事共同推举独立董事张腾文召集并主持。应出 席独立董事3人，实际出席独立董事3人。 全体独立董事本着认真、负责的态度，在认真阅读公司提供的资料，听取有 关人员的汇报并详细了解有关情况后，经出席会议的独立董事审议和表决，形成 以下决议： （一）审议通过《2024年半年度募集资金存放与使用情况的专项报告》 ...

单位：人民币元 四川久远银海软件股份有限公司 2024年半年度募集资金存放与使用情况的专项报告 根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）、《深圳证券交易所上市公 司自律监管指引第 1 号——主板上市公司规范运作》以及《深圳证券交易所上市公司自律监 管指南第 2 号——公告格式》的相关规定，本公司就 2024 半年度募集资金存放与使用情况 作如下专项报告： 一、 募集资金基本情况 (一)实际募集资金金额、资金到账时间 四川久远银海软件股份有限公司 2024年半年度募集资金存放与使用情况的专项报告 经中国证券监督管理委员会证监许可[2017] 1504 号《关于核准四川久远银海软件股 份有限公司非公开发行股票的批复》核准，本公司由主承销商广发证券采取定价方式， 向特定投资者非公开发行人民币普通股股票（A 股）12,540,592.00 股,发行价格为人 民币 35.72 元/股，募集资金总额为人民币 447,950,000.00 元。2018 年 1 月 25 日，广 发证券股份有限公司扣除承销费及保荐 ...

证券代码：002777 证券简称：久远银海 公告编号：2024-025 四川久远银海软件股份有限公司 第六届监事会第四次会议决议的公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 四川久远银海软件股份有限公司（以下简称"公司"）第六届监事会第四次会议通知 于 2024 年 8 月 16 日以专人送达、电子邮件、电话等方式发出。会议于 2024 年 8 月 27 日 以通讯形式召开。会议应参加表决的监事 5 人，实际参加表决的监事 5 人。会议由监事会 主席侯春梅女士主持，会议的召集和召开符合《公司法》以及《公司章程》的规定，会议 决议合法有效。经过全体监事充分讨论，以记名投票的方式审议通过全部议案并形成如下 决议： 一、审议通过了《2024年半年度报告及其摘要》的议案 经审核，与会监事认为，公司董事会编制和审核《2024年半年度报告》和《公司2024 年半年度报告摘要》的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：5票同意, 0票反对，0票弃权。该议 ...

第一条 为规范四川久远银海软件股份有限公司（以下简称"公司"）选聘 会计师事务所行为，提高财务信息质量和审计质量，根据《中华人民共和国公 司法》《中华人民共和国会计法》《上市公司治理准则》《国有企业、上市公 司选聘会计师事务所管理办法》及《公司章程》等相关法律法规和制度，制定 本办法。 四川久远银海软件股份有限公司 选聘会计师事务所管理办法 第一章 总 则 第二条 本办法所称选聘会计师事务所，是指公司根据相关法律法规要求， 聘任会计师事务所对财务会计报告和内部控制发表审计意见、出具审计报告的 行为。聘任会计师事务所从事其他专项审计业务的，视重要性程度可参照本办 法执行。 第三条 公司选聘、续聘、改聘会计师事务所应经董事会审计委员会（以下 简称"审计委员会"）审议同意后，提交董事会审议，并由股东大会决定。公 司不得在董事会、股东大会审议前聘请会计师事务所开展年度财务报告和内部 控制审计业务。 第四条 公司控股股东、实际控制人、持有公司5%以上股份的股东不得在董 事会、股东大会审议前，指定会计师事务所，也不得干预审计委员会独立履行 审核职责。 第二章 职责分工 第五条 资金财务部门负责协助审计委员会进行年度审计会 ...

证券代码：002777 证券简称：久远银海 公告编号： 2024-023 四川久远银海软件股份有限公司 第六届董事会第六次会议决议的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 一、董事会会议召开情况 四川久远银海软件股份有限公司（以下简称"公司"）第六届董事会第六次会议于2024年8 月2日以通讯方式召开，会议应出席表决的董事9人，实际出席表决的董事9人。会议的召开符 合《中华人民共和国公司法》、《公司章程》和《公司董事会议事规则》等规范性文件的有关规 定。 二、董事会会议审议情况 会议以记名投票方式对各项议案进行表决，审议通过如下议案： （二）、《关于公司2024年度经营团队业绩考核方案的议案》 本议案已经第六届董事会独立董事第五次专门会议审议通过。 表决结果：7票同意，0 票反对，0 票弃权，2票回避。 关联董事连春华、乔登俭回避表决本议案。 该议案获得通过。 三、备查文件 1、经公司与会董事签字的《四川久远银海软件股份有限公司第六届董事会第六次会议决 议》； 2、公司第六届董事会独立董事第五次专门会议决议。 特此公告。 四川久远银海软件股份有限 ...

全体独立董事本着认真、负责的态度，在认真阅读公司提供的资料，听取有 关人员的汇报并详细了解有关情况后，经出席会议的独立董事审议和表决，形成 以下决议： 一、审议通过《关于公司2024年度经营团队业绩考核方案的议案》 表决结果：同意3票，反对0票，弃权0票。 四川久远银海软件股份有限公司 第六届董事会独立董事第五次专门会议决议 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》等相 关法律法规、规范性文件以及《四川久远银海软件股份有限公司独立董事专门会 议工作制度》的相关规定，四川久远银海软件股份有限公司（以下简称"公司" 或"本公司"）于2024年8月2日以通讯方式召开第六届董事会独立董事第五次专 门会议。 本次会议由公司过半数独立董事共同推举独立董事李彦召集并主持。应出席 独立董事3人，实际出席独立董事3人。 经营团队业绩考核方案是依据公司所处行业及市场同类企业薪酬水平，并结 合公司的实际经营情况和相关人员的履职情况制定的，符合公司的薪酬政策和激 励机制。不存在损害公司及股东利益情形，符合相关法律、法规及《公司章程》 的规定。同意将该方案提交董事会审议。在审议上述议案时，关联董事应回避表 决。 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative increase of over 15% in the stock price compared to the benchmark index over the next 6 to 12 months [4]. Core Views - The company is experiencing short-term pressure on performance, with stable order growth. The revenue recognition is affected by macroeconomic factors, leading to a year-on-year decline in revenue. However, the company has a sufficient backlog of orders and is expected to achieve its annual operational goals [9][10]. - The company anticipates a revenue of 3.63 billion yuan to 4.15 billion yuan for the first half of 2024, representing a year-on-year decline of 20% to 30%. The net profit is expected to be between 85.136 million yuan and 127.703 million yuan, reflecting a decrease of 85% to 95% [10]. Summary by Sections Financial Performance - Revenue (in million yuan): - 2022A: 1,283 - 2023A: 1,347 - 2024E: 1,554 - 2025E: 1,778 - 2026E: 2,048 - Year-on-year growth rates: - 2023A: 5% - 2024E: 15% - 2025E: 14% - 2026E: 15% [10]. Profitability Metrics - Net Profit (in million yuan): - 2022A: 184 - 2023A: 168 - 2024E: 200 - 2025E: 230 - 2026E: 272 - Year-on-year growth rates: - 2023A: -9% - 2024E: 19% - 2025E: 15% - 2026E: 18% [10]. Valuation Ratios - P/E Ratios: - 2023: 30.5 - 2024E: 28.1 - 2025E: 24.4 - 2026E: 20.7 - P/B Ratios: - 2023: 3.6 - 2024E: 3.1 - 2025E: 2.9 - 2026E: 2.6 [10]. Business Development - The company is accelerating its data element business layout, with successful project implementations. The new business model is expected to open new growth opportunities. The company has launched new products in the healthcare sector, enhancing its service capabilities [10].